Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer

• Published in: Urologic oncology Vol. 41; no. 11; pp. 454.e9 - 454.e16
• Main Authors: Shore, Neal D., Polikarpov, Dmitry M., Pieczonka, Christopher M., Henderson, R. Jonathan, Bailen, James L., Saltzstein, Daniel R., Concepcion, Raoul S., Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Levin, Rachel A., Wissmueller, Sandra, Le, Thao Ho, Gillatt, David A., Chan, Daniel W., Deng, Niantao, Siddireddy, Jaya Sowjanya, Lu, Yanling, Campbell, Douglas H., Walsh, Bradley J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2023
• Subjects: Biomarker; Biopsy; Clinical study; Clinically significant cancer; Humans; Male; NPV; Predictive Value of Tests; Prostate; Prostate - pathology; Prostate-Specific Antigen; Prostatic Neoplasms - pathology; Biomarker; Clinically significant cancer; NPV; Prostate; Clinical study

•MiCheck® Prostate was developed to identify men with clinically significant prostate cancer.•The MiCheck® algorithm combines three blood marker results and a DRE result to give a risk score.•The test has AUC 0.85, sensitivity 95% and specificity 50% for clinically significant prostate cancer. There...